Oral Mucositis Clinical Trials 2024: FDA Approvals, Medication, Treatment Market, Therapies, MOA, ROA, Companies by DelveInsight

(Albany, United States) As per DelveInsight's assessment, globally, the Oral Mucositis Pipeline constitutes 10+ Oral Mucositis companies continuously working towards developing 10+ Oral Mucositis Pipeline treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.

To explore more information on the latest breakthroughs in the Oral Mucositis Pipeline treatment landscape of the report, click here @ Oral Mucositis Pipeline Outlook- https://www.delveinsight.com/report-store/oral-mucositis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Takeaways from the Oral Mucositis Pipeline Report
• DelveInsight's Oral Mucositis Pipeline analysis depicts a robust space with 10+ active players working to develop 10+ pipeline treatment therapies.
• The leading companies are working in the Oral Mucositis Market include Galera Therapeutics, Soligenix, Izun Pharma, MitoImmune Therapeutics, Tosk, Cellix Bio, Enzychem Lifesciences, Monopar Therapeutics, and others.
• Promising Oral Mucositis Pipeline Therapies in the various stages of development include Benzydamine, Dentoxol, RRx-001, IZN-6N4, SGX942, Ectoin Mouth Wash, GC4419 90mg, Melatonin oral gel 3%, Clonidine Lauriad® 50µg, amlexanox, and others.
• Aprili 2024:- EpicentRx, Inc.- A Randomized Placebo-Controlled Trial of Two Schedules of RRx-001 for the Attenuation of Severe Oral Mucositis in Patients Receiving Concomitant Chemoradiation for the Treatment of Locally Advanced Squamous Cell Carcinoma of the Oral Cavity or Oropharynx. The purpose of this study is to determine if RRx-001, which is added on to the cisplatin and radiation treatment, reduces the incidence of severe oral mucositis in patients with head and neck cancers. All patients in this study will receive 7 weeks of standard of care radiation therapy given with the chemotherapy agent, cisplatin. Patients will receive RRx-001 or placebo before start of standard of care treatment.
• April 2024:- Wake Forest University Health Sciences- Phase II Randomized Trial of an Oral Formulation Containing a Mucoadhesive Polymer Hydrogel Vehicle (MucoLox®) to Mitigate Mucositis Symptoms in Head/Neck Cancer Patients Receiving Radiation ± Chemotherapy. This study will examine if the administration of prophylactic MucoLox formulation versus sodium bicarbonate mouthwash in subjects with head/neck cancer receiving radiation ± chemotherapy will result in significantly fewer subjects experiencing severe mucositis.

Oral Mucositis Overview
Mucositis occurs when cancer treatments break down the rapidly divided epithelial cells lining the gastro-intestinal tract (which goes from the mouth to the anus), leaving the mucosal tissue open to ulceration and infection. Mucosal tissue, also known as mucosa or the mucous membrane, lines all body passages that communicate with the air, such as the respiratory and alimentary tracts, and have cells and associated glands that secrete mucus.

For further information, refer to the detailed Oral Mucositis Unmet Needs, click here for Oral Mucositis Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/oral-mucositis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Oral Mucositis Emerging Drugs Profile

• GC4419: Galera Therapeutics
GC4419, also known as avasopasem manganese, has successfully completed two clinical trials in which it was evaluated for reduction of severe oral mucositis in patients with head and neck cancer undergoing radiation therapy and also receiving cisplatin, a chemotherapy drug. The drug is currently in phase III stage of clinical trial evaluation to treat Oral Mucositis.

• SGX942: Soligenix
SGX942 is unique in its mechanism addressing the underlying innate immune dysfunction that contributes to the severity and duration of mucositis. Administered twice weekly by a brief 4-minute IV infusion during chemoradiation treatment while patients are otherwise present at their clinician's office or hospital, SGX942 may be a clinically convenient and safe approach to mitigating oral mucositis. Company's pivotal Phase 3 clinical study ("DOM-INNATE") for oral mucositis in head and neck cancer patients has completed enrollment.

Oral Mucositis Pipeline Therapeutics Assessment
There are approx. 10+ key companies which are developing the therapies for Oral Mucositis. The Oral Mucositis companies which have their Oral Mucositis drug candidates in the most advanced stage, i.e. phase III include, Soligenix.

Request a sample and discover the recent advances in Oral Mucositis Ongoing Clinical Trial Analysis and Medications, Click here for more details @ Oral Mucositis Segmentation- https://www.delveinsight.com/sample-request/oral-mucositis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Oral Mucositis Drugs and Companies
• Melatonin oral gel 3%: Spherium Biomed
• Clonidine Lauriad® 50µg: Onxeo
• Amlexanox: Access Pharmaceuticals Inc.
• Soluble beta-1,3/1,6-glucan: Biotec Pharmacon ASA

Oral Mucositis Therapeutics Assessment
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

Some of the Companies in the Oral Mucositis Therapeutics Market include-
Galera Therapeutics, Soligenix, Izun Pharma, MitoImmune Therapeutics, Tosk, Cellix Bio, Enzychem Lifesciences, Monopar Therapeutics, and others.

Dive deep into rich insights for drugs for Oral Mucositis Pipeline, click here @ Oral Mucositis Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/oral-mucositis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Scope of the Oral Mucositis Pipeline Report
• Coverage- Global
• Oral Mucositis Companies- Galera Therapeutics, Soligenix, Izun Pharma, MitoImmune Therapeutics, Tosk, Cellix Bio, Enzychem Lifesciences, Monopar Therapeutics, and others.
• Oral Mucositis Therapies- Benzydamine, Dentoxol, RRx-001, IZN-6N4, SGX942, Ectoin Mouth Wash, GC4419 90mg, Melatonin oral gel 3%, Clonidine Lauriad® 50µg, amlexanox, and others.
• Oral Mucositis Segmentation: Product Type, Molecule Type, Route of Administration

Got Queries? Find out the related information on Oral Mucositis Merger and acquisitions, Licensing Activities- https://www.delveinsight.com/sample-request/oral-mucositis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Content
1. Introduction
2. Executive Summary
3. Oral Mucositis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Oral Mucositis - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. SGX942: Soligenix
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. MIT-001: MitoImmune Therapeutics
12. Drug profiles in the detailed report…..
13. Inactive Products
14. Oral Mucositis Key Companies
15. Oral Mucositis Key Products
16. Oral Mucositis- Unmet Needs
17. Oral Mucositis- Market Drivers and Barriers
18. Oral Mucositis- Future Perspectives and Conclusion
19. Oral Mucositis Analyst Views
20. Oral Mucositis Key Companies
21. Appendix

Trending Report:
• Bronchiolitis Obliterans Syndrome Bos Market: https://www.delveinsight.com/report-store/bronchiolitis-obliterans-syndrome-market
• Burkitt Lymphoma Market: https://www.delveinsight.com/report-store/burkitt-lymphoma-market
• Cardiac Restoration Systems Market: https://www.delveinsight.com/report-store/cardiac-restoration-systems-market
• Cardiorenal Syndrome Market: https://www.delveinsight.com/report-store/cardiorenal-syndrome-market
• Central Retinal Venous Occulsion Market: https://www.delveinsight.com/report-store/retinal-vein-occlusion-market
• Cerebral Aneurysm Market: https://www.delveinsight.com/report-store/intracranial-aneurysms-market-insight
• Checkpoint Inhibitor Refractory Cancer Market: https://www.delveinsight.com/report-store/checkpoint-inhibitor-refractory-cancer-market
• Cholangiocarcinoma Market: https://www.delveinsight.com/report-store/cholangiocarcinoma-cca-market-insights-epidemiology-and-market-forecast
• Chronic Cutaneous Ulcer Market: https://www.delveinsight.com/report-store/chronic-wounds-market-report
• Chronic Lymphocytic Leukemia Cll Market: https://www.delveinsight.com/report-store/chronic-lymphocytic-leukemia-cll-market
• Chronic Lymphocytic Leukemia Market: https://www.delveinsight.com/report-store/chronic-lymphocytic-leukemia-cll-market
• Chronic Myelogenous Leukemia Market: https://www.delveinsight.com/report-store/chronic-myelocytic-leukemia-cml-market
• Cluster Headache Market: https://www.delveinsight.com/report-store/cluster-headache-market
• Contusion Market: https://www.delveinsight.com/report-store/contusion-market
• Dlbcl Market: https://www.delveinsight.com/report-store/diffuse-large-b-cell-lymphoma-market
• Epithelioid Sarcoma Market: https://www.delveinsight.com/report-store/epithelioid-sarcoma-market
• Exophthalmos Market: https://www.delveinsight.com/report-store/exophthalmos-market
• Facioscapulohumeral Muscular Dystrophy Market: https://www.delveinsight.com/report-store/facioscapulohumeral-muscular-dystrophy-market
• France Healthcare Outlook Report: https://www.delveinsight.com/report-store/france-healthcare-outlook-report
• Gene And Cell Therapies In Rare Disorder Market: https://www.delveinsight.com/report-store/gene-and-cell-therapies-in-rare-disorder-market
• Generalized Anxiety Disorder Market: https://www.delveinsight.com/report-store/generalized-anxiety-disorder-gad-market
• Global Electrophysiology Devices Market: https://www.delveinsight.com/report-store/electrophysiology-devices-market
• Gouty Arthritis Market: https://www.delveinsight.com/report-store/gout-market
• Head And Neck Cancer Market: https://www.delveinsight.com/report-store/head-and-neck-cancer-hnc-market
• Hepatitis D Market: https://www.delveinsight.com/report-store/hepatitis-d-market
• Hiatal Hernia Market: https://www.delveinsight.com/report-store/hiatal-hernia-market

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting/conference-coverage-services

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.